Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, discusses the substantial overuse of aggressive medical care for younger patients at the end of life, despite ASCO recommendations (Abstract LBA10033).
Maria Clemence Schwaederle, PharmD, of the University of California, San Diego, discusses an analysis of 13,203 patients in phase I clinical trials, which showed that a personalized strategy led to improved response rate and progression-free survival (Abstract 11520).
Lisa A. Carey, MD, of the University of North Carolina, and Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital and Institute of Cancer Research, discuss the efficacy of palbociclib plus fulvestrant in patients with ESR1 mutations in circulating tumor DNA, and palbociclib and letrozole for postmenopausal women with ER+/HER2–advanced breast cancer (Abstracts 507, 524).
Usha Menon, MD, of University College London, discusses a significant new version of a screening test for ovarian cancer that may reduce death from the disease (Abstract 5507).
Newly elected ASCO President Daniel F. Hayes, MD, of the University of Michigan Health System Comprehensive Cancer Center, talks about his vision for the society during his tenure.
Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.
